Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Who Wouldn't Be Here Without Axcan's Photofrin Should Disappear Now, FDA Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Web videos featuring overblown patient testimonials prove an easy target for DDMAC.

You may also be interested in...



DDMAC Numb To Purported Advantages Of Dental Anesthetic

Warning letter continues FDA's trend of citing superiority claims based on the route of administration.

DDMAC Numb To Purported Advantages Of Dental Anesthetic

Warning letter continues FDA's trend of citing superiority claims based on the route of administration.

Luvox CR Symptom Benefit Claims Draw DDMAC Warning

An FDA warning letter to Jazz Pharmaceuticals citing a Luvox CR (fluvoxamine maleate) patient brochure continues an agency trend of targeting efficacy claims about individual symptoms of a broader disease state

Related Content

Topics

UsernamePublicRestriction

Register

PS071102

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel